Recent Federal Awards
| Award | Agency | Amount | Date |
|---|---|---|---|
| A PHASE 1 PLACEBO-CONTROLLED DOSE-ESCALATION SAFETY AND PHARMACOKINETIC STUDY OF IN-007, A NEBULIZED, PAN-SARS | Department of Defense | $3.2M | |
| DEVELOPING IN-007 AS A WIDELY DEPLOYABLE INHALED TREATMENT AGAINST PATHOGENS UTILIZING HUMAN ACE2 FOR VIRAL AT | Department of Defense | $2.2M |
Is this your company?
Claim this profile to keep it accurate — and see the federal & state opportunities GovIntel's AI has matched to INHALON BIOPHARMA, INC. right now.
Claim this profile See matched opportunitiesData compiled from public government sources including SAM.gov, USAspending.gov, and state procurement records. Last verified against federal award records. Inaccurate? Let us know.